Status:
COMPLETED
A Study of Dasatinib (BMS-354825) in Patients With Advanced 'Triple-negative' Breast Cancer
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Breast Cancer
Metastasis
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced triple-negative breast cancer.
Eligibility Criteria
Inclusion
- females, 18 or older
- recurrent or progressive locally advanced, or 'triple negative' metastatic breast cancer
- paraffin-embedded tissue block must be available
- measurable disease
- prior chemotherapy with an anthracycline, a taxane, or both (neoadjuvant, adjuvant, or metastatic setting)
- 0, 1 or 2 chemotherapies in the metastatic setting
- adequate organ function
Exclusion
- Metastatic disease confined to bone only
- Symptomatic CNS metastasis
- Concurrent medical condition which may increase the risk of toxicity
- Unable to take oral medication
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT00371254
Start Date
December 1 2006
End Date
September 1 2008
Last Update
March 15 2011
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
Ucsf-Comprehensive Cancer Center
San Francisco, California, United States, 94143
2
Mayo Clinic Jacksonville
Jacksonville, Florida, United States, 32224
3
Dana-Farber Cancer Inst
Boston, Massachusetts, United States, 02115
4
Montefiore Medical Center
The Bronx, New York, United States, 10461